| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dd98ad4ee076841fec541542f952f58 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2015-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efe8ac8560c99e323e08ca6bf291bf62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_378c495be1532019badcc27f48828512
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ccef122b748e841cb215c897a1372ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19d14b0c29b9598dd33d2c688616478a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43d678eba1e9d7c78e3b7e26200c8134 |
| publicationDate |
2017-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-2016010799-A |
| titleOfInvention |
COMPOSITIONS FOR SENSITIZATION TO PARASITE FARMACO. |
| abstract |
Compositions and methods for inhibiting and / or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions may comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug sensitization in a parasite. The methods may comprise the administration of a rifamycin derivative or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug sensitization in the parasite. |
| priorityDate |
2014-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |